dyceco glp-1 GLP-1s Doctors warn GLP-1 users about

An e-diary specifically designed to inquire about the presence of GI symptomatology (for example, nausea, vomiting, constipation, diarrhea) and their intensity (using a visual analog scale), was proactively used to record and transmit data on AEs and participant-reported outcomes, daily for 7 days, after each dose titration step (every 4 weeks), as well as recording daily medication taken (including date and time of dosing)

Currently, the single-agonist segment holds the maximum share of the GLP-1 market

Bioactive Iridium nanoclusters with glutathione depletion ability for enhanced sonodynamic-triggered ferroptosis-like cancer cell death

In the open-label SURMOUNT-5 trial (751 participants without diabetes), it was compared head-to-head with semaglutide